The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Tamaru S, Tono Y, Matsumoto T, Oda H, Sugimoto Y, Mizuno T, Katayama N, Nishikawa M

Successful treatment by prednisolone for interstitial pneumonia associated with anagrelide in a patient with essential thrombocythemia.

International cancer conference journal. 2017;6(1):22-24

Singh A, Parthvi R

Anagrelide Therapy Complicated by Pneumonitis: Drug Toxicity or Lupus Flare?

American journal of therapeutics. 2019;26(6):e792-e793

Kajiguchi T, Kamoshita S, Ito T, Yagi M, Kimura T

[Drug-induced interstitial pneumonitis in essential thrombocythemia treated with anagrelide].

[Rinsho ketsueki] The Japanese journal of clinical hematology. 2017;58(2):119-125

Spencer EM, Lawrence DS

'Double hit' from streptococcal pneumonia and hypersensitivity pneumonitis associated with anagrelide.

Clinical and laboratory haematology. 2006;28(1):63-5